SCHEMBL24809164

SCHEMBL24809164

Cc1c(Oc2cc(F)c3c(c2)ncn3C)ccc(N)c1F

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BRAF P15056 12/20 0.34
DPP4 P27487 1/20 0.33
ERBB2 P04626 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050974 1.00 BRAF (0.34) BRAFDPP4ERBB2
SCHEMBL24807693 0.84 DPP4 (0.34) DPP4ERBB2
SCHEMBL31693489 0.84 DPP4 (0.34) DPP4ERBB2
Hydrochloric Acid SCHEMBL31257322 0.83 DPP4 (0.33) DPP4ERBB2
SCHEMBL30050420 0.82 GRM5 (0.42) BRAFERBB2
SCHEMBL24807701 0.82 GRM5 (0.42) BRAFERBB2
SCHEMBL24569478 0.82 KMT2A (0.44) ERBB2
SCHEMBL29887844 0.82 KMT2A (0.44) ERBB2
SCHEMBL30049938 0.82 ALDH1A1 (0.36) BRAF
SCHEMBL31257309 0.81 DPP4 (0.32) DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117940425-A HER2 mutation inhibitors 阿雷生物药品公司 2024-04-26 CN disclosed
US-20230041385-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2023-02-09 US disclosed
WO-2022269531-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230041385-A1 HER2 MUTATION INHIBITORS ERBB2, EGFR, ERBB3 BRAF 24/4885DPP4 4119/4885ERBB2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.